Antibodies targeting the receptor binding site (RBS) of the influenza virus hemagglutinin (HA) protein are usually not broadly reactive because their footprints are typically large and extend to nearby variable HA residues. Here, we identify several human H3N2 HA RBS-targeting monoclonal antibodies (mAbs) that are sensitive to substitutions in conventional antigenic sites and are therefore not broadly reactive. However, we also identify an H3N2 HA RBS-targeting mAb that is exceptionally broadly reactive despite being sensitive to substitutions in residues outside of the RBS. We show that similar antibodies are present at measurable levels in the sera of This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
INTRODUCTION
Influenza viruses continuously infect humans, in large part due to their ability to rapidly escape human immunity (Yewdell, 2011) . Most neutralizing antibodies against influenza viruses target the globular head domain of hemagglutinin (HA) proteins and inhibit viral replication by blocking viral attachment. These types of antibodies often become ineffective after viruses acquire substitutions in epitopes within the HA globular head through a process called antigenic drift. As a result, seasonal influenza virus infections or vaccinations typically provide limited protection against antigenically drifted strains. New "universal" vaccine antigens are currently being developed to elicit broadly reactive antibodies against conserved epitopes in the HA receptor binding site (RBS) (Giles and Ross, 2011; Kanekiyo et al., 2019) as well as the HA stalk region (Impagliazzo et al., 2015; Krammer et al., 2013; Yassine et al., 2015) .
New universal vaccines that elicit antibodies against conserved epitopes in the HA RBS are attractive since antibodies against this region of HA directly block viral attachment and are highly neutralizing (Krause et al., 2011; Whittle et al., 2011) . However, it is difficult to design vaccine antigens to elicit broadly neutralizing HA RBS-reactive antibodies because the surface area of most antibody footprints is larger than the narrow conserved RBS (Knossow and Skehel, 2006) . The HA RBS is approximately 800 Å 2 (Weis et al., 1988) , whereas most antibody footprints are 1,200-1,500 Å 2 (Amit et al., 1986) .
Several broadly neutralizing antibodies that target conserved residues in the HA RBS have been identified Krause et al., 2011; Lee et al., 2012 Lee et al., , 2014 McCarthy et al., 2018; Schmidt et al., 2015b; Tsibane et al., 2012; Whittle et al., 2011; Winarski et al., 2015; Xu et al., 2013) . These antibodies can arise from a number of V H gene segments (McCarthy et al., 2018; Schmidt et al., 2015b) . Most of these HA RBS-targeting antibodies bind through molecular mimicry, imitating the HA cellular receptor, sialic acid. Some of these broadly reactive antibodies make contact with conserved RBS residues through a shared dipeptide motif (Krause et al., 2011; Lee et al., 2014; Schmidt et al., 2015b; Whittle et al., 2011) , while other antibodies insert a hydrophobic residue into the RBS (Lee et al., 2014; Xu et al., 2013) . Most broadly reactive HA RBS-targeting antibodies have long heavychain complementarity determining regions (HCDRs) that allow the sialic acid-mimic motif of the antibody to be guided into the conserved RBS while minimizing contacts to variable residues on the rim of the RBS Lee et al., 2014; Whittle et al., 2011; Xu et al., 2013) .
Here, we delineated the binding and neutralization characteristics of a large panel of anti-H3 human monoclonal antibodies (mAbs) that were isolated following seasonal influenza vaccination. We found that a large proportion (>25%) of these mAbs targeted epitopes in the HA RBS. While most of these HA RBS-targeting mAbs were sensitive to substitutions in adjacent antigenic sites and were not broadly reactive, we identified one mAb that maintained broad reactivity despite being moderately sensitive to substitutions at residues inside and outside of the RBS. We completed a series of experiments to further characterize this mAb and determined that some individuals have high levels of similar antibodies in polyclonal sera. targeted epitopes in the HA globular head domain. All HAI + mAbs also neutralized the A/ Victoria/210/2009 strain in vitro ( Figure 1B ). We identified 7 HAI − mAbs ( Figure 1A) , and we found that two of these mAbs neutralized virus in vitro, while the remaining five were non-neutralizing ( Figure 1B ). The two HAI − neutralizing mAbs inhibited binding of the HA stalk-reactive F49 mAb in competition assays ( Figure S1 ), suggesting that these mAbs targeted epitopes in lower regions of HA. These data are consistent with previous studies (Angeletti and Yewdell, 2018) that suggest that the majority of antibodies elicited by seasonal influenza vaccines target neutralizing epitopes on the HA globular head.
Most Vaccine-Elicited Human H3 mAbs Target HA Antigenic Site B
We then measured binding of each mAb to a panel of A/Victoria/210/2009 HAs that had different amino acid substitutions. For this, we created virus-like particles (VLPs) with A/ Victoria/210/2009 HAs with substitutions in classic antigenic sites (Koel et al., 2013; Wiley et al., 1981) and antigenic sites that have recently changed in naturally circulating human viral strains (Hadfield et al., 2018) . Most of the substitutions in our panel were located in the 140 loop of antigenic site A as well as the 150 loop and 190 helix of antigenic site B near the HA RBS, but we also included several substitutions in the lower part of the HA head ( Figure 2A ). We also included HAs with substitutions in conserved residues within the RBS ( Figure 2B ), so that we could identify HA RBS-targeting mAbs. In total, we tested binding of all 33 mAbs using a panel of VLPs that expressed the wild-type (WT) and 24 different mutant forms of A/Victoria/210/2009 HAs in ELISAs ( Figure 2C ).
The majority (73%) of HAI + mAbs in our panel were sensitive to substitutions in HA antigenic site B. Substitutions at residues 157, 159, and 160 of HA antigenic site B abrogated the binding of ~61% of HAI + mAbs, whereas substitutions at other antigenic site B residues (155, 156, 189, 192, 193) affected the binding of fewer mAbs. We identified a few mAbs that were sensitive to substitutions in antigenic site A or epitopes lower on HA that were further from the RBS. Only three mAbs in our panel were sensitive to substitutions in antigenic site A, and 7 mAbs were sensitive to substitutions in residues lower on HA. These data suggest that antigenic site B is the major target of human neutralizing HA antibodies to recent H3N2 strains and demonstrate that single substitutions near the RBS can abrogate the binding of most human mAbs.
While our data indicating that most of the mAbs in our panel are HA site B specific are consistent with previous studies (Chambers et al., 2015; Popova et al., 2012; Zost et al., 2017) , we were surprised to find that ~1/3 of our HAI + mAbs were sensitive to substitutions in conserved positions in the HA RBS ( Figure 2C ). Most of the mAbs in our panel that were sensitive to RBS substitutions were also sensitive to site B substitutions ( Figure 2C ). However, several mAbs that targeted the HA RBS were only moderately affected by site B substitutions. For example, the 019-10117-3C06 mAb, which was moderately sensitive to RBS and site B substitutions, maintained partial binding to all of the mutant HAs that we tested. These data reveal that seasonal influenza vaccines elicit robust antibody responses targeting conserved residues within the HA RBS and that at least some of these antibodies can maintain partial binding to HAs that have substitutions in conventional antigenic sites adjacent to the RBS.
Identification of an HA RBS Targeting mAb with Exceptional Breadth
We measured binding of each mAb to HAs from H3N2 viruses isolated before and after the 2010-2012 seasons. As expected, most HAI − mAbs bound broadly to H3 HAs isolated from 1968-2014 and two HAI − mAbs bound to both H3s and H1 HAs (Figure 3 ). In contrast, the majority of HAI + mAbs bound to a narrow range of HAs from viruses that circulated from 2005-2012 ( Figure 3 ). Most HAI + mAbs failed to recognize an HA from a recent 2014 clade 3C.2a H3N2 strain (Chambers et al., 2015; Zost et al., 2017) that has a more antigenically evolved HA antigenic site B (Figure 3 ). Interestingly, two HAI + mAbs (019-10117-3C06 and 028-10134-4F03) had exceptionally broad reactivity, binding to every H3 HA in our panel. One of these mAbs (028-10134-4F03) was sensitive to substitutions in residues 121 and 150 ( Figure 2B ) in the mid region of the HA head ( Figure 2A ). The second broadly reactive HAI + mAb (019-10117-3C06) is particularly interesting because it is one of the HA RBS-targeting mAbs that we determined to be only moderately sensitive to substitutions in classic antigenic site B ( Figure 2B ). Despite having moderate reductions in binding to HAs with antigenic site B substitutions and RBS substitutions, the 019-10117-3C06 mAb partially bound to every H3 HA in our panel, including the more recent 2014 clade 3C2.a HA ( Figure 3 ).
The 019-10117-3C06 mAb originates from the IGHV1-69*01 germline and has 29 heavychain somatic mutations relative to germline, 16 of which result in coding changes ( Figure  S2 ). Previous studies have identified IGHV1-69 mAbs targeting the H2 RBS (Xu et al., 2013) , H3 RBS (Lee et al., 2014) , and HA stalk (Ekiert et al., 2009; Kashyap et al., 2008; Pappas et al., 2014; Sui et al., 2009 ). 019-10117-3C06 has a 19 amino acid HCDR3 ( Figure  S2 ), which is a similar length to that of previously reported H1 RBS mAbs such as CH65 and others (Schmidt et al., 2015b; Whittle et al., 2011) . The 019-10117-3C06 mAb also has a JH6 gene segment, which has been reported as a common feature of mAbs recognizing the H1 RBS (Schmidt et al., 2015b) but lacks the dipeptide motif that is present in many previously described H1 and H3 RBS mAbs (Lee et al., 2014; Schmidt et al., 2015b) .
Characterization of a Broadly Reactive HA RBS Targeting mAb
We used deep mutational scanning (Doud et al., 2017; Doud et al., 2018; Lee et al., 2018) to unbiasedly identify HA amino acid substitutions that could facilitate viral escape from the 019-10117-3C06 mAb. For these experiments, we used a library of A/Perth/16/2009 HAs (which is antigenically similar to A/Victoria/210/2009) that had every possible single amino acid substitution in HA. We grew this virus library in the presence or absence of the 019-10117-3C06 mAb. For comparison, we completed parallel experiments in which we grew the virus library in the presence of an HA antigenic site B mAb (024-10128-3C04) that did not have broad reactivity. The narrowly reactive 024-10128-3C04 HA site B mAb selected viruses with substitutions in residues 159, 160, 192, and 193 , which are located in HA antigenic site B ( Figure 4A ). Interestingly, the broadly reactive 019-10117-3C06 mAb also selected for viruses with HAs that had substitutions in antigenic site B (residues 159, 160, 193) , as well as HAs that had substitutions in the adjacent antigenic site A (residue 145) ( Figure 4B ). Viruses with substitutions in conserved residues of the HA RBS were not enriched in these experiments, which is expected since viruses with HA RBS substitutions do not usually replicate efficiently.
To further characterize HA amino acid substitutions identified in our deep mutational scanning experiments, we completed neutralization assays using viruses engineered to express A/Perth/16/2009 HAs with the N145D, F159G, F159S, K160T, or I192E substitutions. As expected, site B substitutions dramatically reduced neutralization of the narrowly reactive 024-10128-3C04 mAb ( Figure 4C ). Substitutions at residues 145, 159, and 160 also reduced neutralization of the 019-10117-3C06 mAb, but importantly, all mutant viruses tested were still moderately neutralized by this mAb ( Figure 4D ). As a control, we also tested binding of the 028-10134-4F03 mAb, which binds lower on the HA head, against the 024-10128-3C04 and 019-10117-3C06 escape mutants. As expected, this mAb neutralized these mutants equivalently ( Figure 4E ). These data indicate that viruses can accommodate HA substitutions that decrease neutralization of the broadly reactive 019-10117-3C06 mAb, but that these substitutions do not allow complete escape from this antibody.
We hypothesized that the 019-10117-3C06 mAb is able to partially recognize viruses with HA antigenic site B substitutions by engaging conserved residues in the HA RBS. To test this hypothesis, we measured antibody binding to HAs that had a K160T HA substitution that introduces a glycosylation site in HA antigenic site B with and without an additional Y98F substitution. HA residue 98 is located at the base of the RBS and interacts directly with sialic acid (Weis et al., 1988 ; Figure 2B ). Previous studies have shown that the Y98F substitution prevents HA binding to sialic acid without affecting the overall structure of HA (Bradley et al., 2011; Martín et al., 1998; Whittle et al., 2014) . The 019-10117-3C06 mAb had reduced binding to HAs that had either the K160T or the Y98F HA substitutions, and the binding of this mAb was further reduced to HAs that had both of these substitutions ( Figure 5A ). As a control, we also tested binding of the narrow 024-10128-3C04 mAb to HAs that had the K160T substitution with or without the Y98F substitution. Unlike the broadly reactive 019-10117-3C06 mAb, the narrow 024-10128-3C04 mAb failed to efficiently bind to HAs that had K160T, with or without the Y98F substitution ( Figure 5B ). This finding suggests that partial binding of the 019-10117-3C06 mAb to HAs with antigenic site B substitutions depends on interactions with the conserved Y98 residue in the RBS.
Broad cross-reactivity of RBS mAbs often requires bivalent binding Hong et al., 2013; Lee et al., 2012) . We used biolayer interferometry (BLI) to measure the binding of 019-10117-3C06 IgG and Fab to A/Perth/16/2009 HA and the antigenically distant A/Hong Kong/1/1968 HA. Both 019-10117-3C06 IgG and Fab bound strongly to A/ Perth/16/2009 HA ( Figures 5C and 5D ). The 019-10117-3C06 IgG, but not the 019-10117-3C06 Fab, bound to the antigenically distant A/Hong Kong/1/1968 HA ( Figures  5E and 5F ). These data suggest that the 019-10117-3C06 mAb relies on bivalent binding in order to maintain broad cross-reactivity with H3 HAs.
Some Individuals Have High Levels of Broadly Reactive HA RBS-Targeting Antibodies
We next completed ELISAs to determine whether HA RBS-targeting antibodies were present at high frequencies in the sera of donors pre-and post-vaccination. We tested sera from 28 individuals vaccinated during the 2010-2011 season, including 10 of the 13 donors that were used to generate mAbs. We tested sera antibody binding to ELISAs coated with A/ Victoria/210/2009 HA, A/Victoria/210/2009 HA with a Y98F RBS substitution, A/Hong Kong/4801/2014 HA (a drifted strain with HA antigenic site B substitutions), and A/Hong Kong/4801/2014 HA with a Y98F RBS substitution. Most serum samples had antibodies that bound similarly to HAs with and without the Y98F substitution ( Figure S3 ). However, serum antibodies from one donor (019-10117) had weaker binding to HAs with the Y98F substitution ( Figure 6 ). Notably, the broadly reactive 019-10117-3C06 HA RBS-targeting mAb was derived from this same donor. This donor had Y98F-sensitive antibodies both before and after vaccination, and the proportion of Y98F-sensitive antibodies decreased slightly after vaccination ( Figure 6 ). Just like the 019-10117-3C06 mAb, polyclonal serum antibodies from this donor partially bound to the drifted A/Hong Kong/4801/2014 HA and binding of these antibodies to this HA was reduced by the Y98F HA substitution.
Evaluation of HA RBS-Targeting Antibodies in Years with Seasonal Influenza Vaccine Mismatches
It is possible that HA RBS-directed antibodies might be an important part of polyclonal neutralizing antibody responses during influenza seasons with substantial antigenic mismatches between vaccine strains and circulating strains. In order to measure serum levels of Y98F-sensitive antibodies, we developed an absorption-based assay, in which we incubated serum antibodies with 293F cells expressing HAs with or without the Y98F substitution and then completed in vitro neutralization assays with HA-absorbed serum fractions. In these assays, antibodies that are sensitive to the Y98F HA substitution are not absorbed by 293F cells that express the Y98F HA.
To validate the assay, we tested the broadly reactive 019-10117-3C06 HA RBS-targeting mAb and a broadly reactive 041-10047-1C04 mAb that does not make contact with the HA RBS. For these experiments, we tested binding and neutralization of the A/Hong Kong/ 4801/2014 viral strain. Absorption with 293F cells expressing the WT A/Hong Kong/ 4801/2014 HA completely removed both antibodies ( Figure 7A ). Conversely, absorption with 293F cells expressing A/Hong Kong/4801/2014 HA with the Y98F substitution removed the 041-10047-1C04 mAb but did not remove the HA RBS-targeting 019-10117-3C06 mAb ( Figure 7A ). We next characterized serum antibodies from 21 individuals that received the 2015-2016 seasonal vaccine. We studied antibody responses elicited against the 2015-2016 vaccine because the H3N2 component of this vaccine was mismatched compared to A/Hong Kong/ 2014-like H3N2 viruses that circulated that season ( Figure 7B ). We first completed standard neutralization assays using the 2015-2016 vaccine strain (A/Switzerland/9715293/2013) and the antigenically distinct A/Hong Kong/4801/2014 virus. As expected, vaccine-elicited antibodies did not neutralize the mismatched A/Hong Kong/4801/2014 virus as efficiently as the vaccine strain ( Figure 7C ). However, the vaccine strain did boost serum antibody responses against A/Hong Kong/4801/2014 in some individuals. In order to determine whether these cross-reactive antibodies were targeting conserved residues of the HA RBS, we completed absorption fractionation assays using serum from the same 21 vaccinated donors. For these experiments, we quantified the fraction of A/Hong Kong/4801/2014-reactive antibodies that were sensitive to the HA Y98F substitution. We detected Y98F HAsensitive A/Hong Kong/4801/2014-reactive antibodies in only 4 of 21 vaccinated donors (Figures 7D-7G; Figure S4 ). We found that absorption with A/Hong Kong/4801/2014 WT HA depleted serum neutralizing antibodies, while absorption with A/Hong Kong/4801/2014 HA-Y98F left an absorption-resistant fraction of neutralizing antibodies. Some of these individuals had detectable RBS-targeting antibodies before vaccination ( Figures 7D-7G ). ELISA quantification confirmed that the antibodies remaining after A/Hong Kong/ 4801/2014 HA-Y98F absorption bound to the A/Hong Kong/4801/2014 WT but not to the A/Hong Kong/4801/2014 HA-Y98F HA, which indicates that this absorption-resistant fraction contained RBS-targeting antibodies ( Figure S5 ). These data indicate that Y98Fsensitive HA RBS antibodies are only detected in the serum of a limited number of vaccines and are not efficiently elicited by vaccination in most individuals.
DISCUSSION
A greater understanding of the specificity of anti-influenza virus antibody responses in humans is useful for rationally designing new universal influenza vaccine antigens. We began this study by antigenically charactering 33 H3 mAbs isolated from humans receiving a seasonal influenza vaccine. We found that the majority of these mAbs targeted epitopes in variable regions of the HA head. Some of these mAbs targeted conserved residues in the HA RBS but were not broadly reactive since they were also highly sensitive to HA substitutions in adjacent variable antigenic sites. However, we identified one HA RBS-targeting mAb that had exceptional breadth. This mAb (019-10117-3C06) was also moderately sensitive to HA substitutions in adjacent variable antigenic sites but was able to partially bind to antigenically drifted HAs.
Most HA RBS-targeting antibodies are not broadly reactive because their large binding footprints lead to contacts outside of the narrow RBS. However, several broadly reactive HA RBS-targeting antibodies have been identified Krause et al., 2011; Lee et al., , 2014 McCarthy et al., 2018; Schmidt et al., 2015b; Tsibane et al., 2012; Whittle et al., 2011; Winarski et al., 2015; Xu et al., 2013) . A common feature of these broadly reactive HA RBS-targeting antibodies is that most have relatively long HCDR3s, which allow them to minimize contacts on the rim of the RBS and maximize contacts with conserved RBS residues. Our study highlights that HA RBS-targeting antibodies can be broadly reactive even if they are moderately sensitive to substitutions in conventional antigenic sites near the RBS. Similar to the previously published F045-092 mAb (Lee et al., 2014) , the 019-10117-3C06 mAb from our study is affected by substitutions in HA antigenic site B (Figure 2 ) but maintains binding to diverse H3 HAs across almost 50 years (Figure 3 ) likely through bivalent binding and multiple contacts with conserved residues in the RBS.
Our study indicates that current vaccines do not efficiently elicit broadly reactive HA RBStargeting antibodies in most individuals. We examined a cohort that received an antigenically mismatched vaccine and, although some of the donors mounted a cross-reactive antibody response, most of these cross-reactive HA antibodies were not Y98F sensitive. It is worth noting that we only measured RBS antibodies that were sensitive to the Y98F HA substitution, and it is possible that current vaccines elicit other types of RBS antibodies that are not Y98F sensitive. Most conventional vaccine antigens are prepared in fertilized chicken eggs (Grohskopf et al., 2018) and contemporary egg-adapted H3N2 vaccine strains have substitutions in or near the RBS that allow more efficient viral growth in chicken eggs (Wu et al., 2017; Zost et al., 2017) . We speculate that vaccines that do not have adaptive mutations in the HA RBS might be better at eliciting antibodies targeting epitopes in the HA RBS of circulating viral strains. Future studies should determine whether vaccine antigens that are not prepared in eggs are better able to elicit broadly reactive HA RBS-targeting antibodies.
The challenge, of course, is designing new vaccine antigens that are able to preferentially elicit antibodies like 019-10117-3C06 and identifying the concentration of these antibodies needed for protection. Recent work has sought to selectively elicit broadly reactive HA head antibody responses through the use of "mosaic" nanoparticles that display antigenically diverse HA RBS domains on the same nanoparticle (Kanekiyo et al., 2019) . This vaccination strategy might selectively activate naive B cells targeting the HA RBS and recall broadly reactive memory B cells in secondary responses. One key challenge moving forward will to be determine whether unique prior exposure histories facilitate the development of broadly reactive HA RBS-targeting antibodies. In our study, we identified some donors with high levels of these antibodies in polyclonal sera. In the case of donor 019-10117, these antibodies were already at high levels in polyclonal sera before vaccination. Is there something genetically unique about donor 019-10117 or does that donor have an unusual exposure history that gave rise to a B cell response highly focused on conserved residues within the HA RBS? While some studies have generated unmutated common ancestors and inferred the immunogenic stimuli for broadly reactive antibody lineages targeting the HA RBS (McCarthy et al., 2018; Schmidt et al., 2015a) , we know little about how prior immune history and repeated exposures influence the development of HA RBS antibodies. In the field of HIV, major efforts have been made to study antibody-virus co-evolution and the development of broadly neutralizing antibody specificities in chronically infected individuals, with the goal of identifying HIV envelope proteins that favor the development of broadly neutralizing antibody responses (Bonsignori et al., 2017; Landais et al., 2017; Rantalainen et al., 2018) . Longitudinal studies in human cohorts could address similar questions for influenza viruses, with the potential to fill in gaps in our understanding of how antibody responses are elicited, recalled, and altered by infection and vaccination (Erbelding et al., 2018) .
Microneutralization (MN) Assays-mAbs were serially diluted two-fold in roundbottom 96-well plates in 50 μL serum-free Minimal Essential Medium (MEM). 50 μL of MEM containing 100 TCID 50 of virus was added to serially diluted mAbs and the mAbvirus mixtures were incubated for 30 min at room temperature. Following incubation, the mAb-virus mixtures were added to confluent monolayers of MDCK cells in 96-well plates and incubated for 1 hr at 37°C. After incubation, the virus-antibody mixtures were removed and cells were washed with 180 μL MEM. After washing, serial dilutions of each mAb were added back to cell monolayers in infection media (MEM containing HEPES buffer, gentamycin, and 1 μg/mL TPCK-treated trypsin). The cells were incubated for 3 days and neutralization titers were determined as the lowest concentration of mAb that prevented cell death. MN assays were completed in duplicate on separate days. VLP Antigenic Mapping ELISAs-Point mutants of A/Victoria/210/2009 HA were generated in a codon-optimized HA gene by site directed mutagenesis. Virus-like particles (VLPs) were generated by transfecting 293T cells with each point mutant along with plasmids encoding HIV gag, the NA from A/Puerto Rico/8/1934, and a human-airway trypsin-like protease (HAT). Supernatants from transfected 293T cells were collected 3 days following transfection and were concentrated by centrifugation at 19,000 rpm (65,096 x g) in an SW-28 rotor using a 20% sucrose cushion. VLP pellets were resuspended in PBS and stored at 4°C. ELISA plates were coated with HA-normalized point mutant VLPs diluted in PBS or just PBS as a background control and stored overnight at 4°C. The following day, plates were blocked with a 3% w/vol solution of bovine-serum albumin (BSA) in PBS for 2 hr. After blocking, plates were washed five times with distilled water and two-fold serial dilutions of each mAb were added to plates in a 1% w/vol solution of BSA in PBS. After 2 hr of incubation, plates were washed and a peroxidase-conjugated goat anti-human secondary antibody was added in a 1% w/vol solution of BSA in PBS. After incubation for 1 hr, plates were washed and 50 μL of TMB substrate was added to each well. The TMB reaction was quenched by addition of 25 μL 250 mM HCl and absorbance at 450nm was measured using a plate reader. In order to generate antigenic maps, one-site specific binding curves were fit to the data in GraphPad Prism software and the maximal binding (B max ) was determined for each mAb. To generate antigenic maps from the ELISA data, we first selected the lowest mAb concentration that still gave at least 90% of the B max signal. At this dilution, background signal was subtracted and signal for each point mutant was normalized to the A/Victoria/210/2009 WT HA VLP signal. Antigenic mapping ELISAs were conducted for each mAb in duplicate on separate days, and the resulting values were averaged and represented as a heatmap.
Seasonal H3N2 Strain ELISAs-A panel of seasonal H3N2
viruses spanning 1968 to 2013 was expanded by propagation in embryonated chicken eggs. Due to egg-adaptive mutations a 2014 strain for the seasonal panel was propagated in MDCK-SIAT1 cells. Supernatants containing virus were clarified by centrifugation and concentrated by ultracentrifugation at 20,000 rpm (71,935 x g) in an SW-28 rotor. Viral pellets were resuspended at 4°C overnight in PBS. Viruses were chemically inactivated using 0.1% (vol/ vol) B-Propiolactone (BPL; Sigma Aldrich) in PBS containing 0.1M HEPES. Viruses were inactivated by incubation with BPL at 4°C overnight followed by incubation at 37°C for 90 min. To measure mAb binding to the seasonal panel, ELISA plates were coated overnight at 4°C with standardized amounts of concentrated virus in PBS. The following day, ELISAs were performed and antigenic maps were generated as described for the VLP antigenic mapping. Seasonal H3N2 strain mapping ELISAs were conducted for each mAb in triplicate on separate days, and the resulting values were averaged and represented as a heatmap.
Recombinant HA Production-Codon optimized HA genes for A/Hong Kong/ 4801/2014 WT and Y98F were cloned into expression vectors and the transmembrane was removed and replaced with the foldon trimerization domain from T4 fibritin, an AviTag sitespecific biotinylation sequence, and a hexahistidine tag, as previously described (Whittle et al., 2014) . Recombinant HAs were produced by transfecting 293F suspension cells with plasmids encoding HA and a membrane-bound NA lacking a His tag. After four days, the supernatant was clarified by centrifugation and the HA proteins were purified by Ni-NTA affinity chromatography. Recombinant HAs for mAb affinity measurements were produced in insect cells using a baculovirus expression system and purified by Ni-NTA affinity chromatography.
Biolayer Interferometry Binding Assay-An Octet Red instrument (ForteBio, Menlo Park, CA) was employed for biolayer interferometry binding (BLI) assays. Baculovirusexpressed recombinant HA was expressed and purified as described previously (Ekiert et al., 2011) . For this, High Five insect cells (Invitrogen) were infected with baculoviruses encoding each recombinant HA fused to a trimerization domain and a C-terminal his tag. HAs were purified from culture supernatants using Ni-NTA affinity chromatography. 019-10117-3C06 Fab was generated from 019-10117-3C06 IgG using papain cleavage as previously described (Bianchi et al., 2018) . For this, full-length IgG was digested using papain-agarose resin (Thermo Fisher Scientific) and Fab was purified by size exclusion chromatography. Recombinant HA (uncleaved HA0) at a concentration of 50 μg/mL in 1 x kinetics buffer (1 x PBS with 0.01% BSA and 0.002% Tween 20) was loaded onto the streptavidin (SA) Biosensors. Binding kinetics were measured against the indicated 019-10117-3C06 IgG or Fab at 125 nM, 250 nM, 500 nM, and 1,000 nM. The assay consisted of five steps: (1) baseline: 60 s with 1x kinetics buffer; (2) loading: 10 mins with biotinylated HA; (3) baseline: 60 s with 1 × kinetics buffer; (4) association: 120 s with purified IgG or Fab; and (5) dissociation: 120 s with 1 x kinetics buffer. The data were fit with a 1:1 binding model for Fab and heterogenous ligand model for IgG to estimate the K d .
Mutational Antigenic Profiling-We performed mutational antigenic profiling of mAbs 024-10128-3C04 and 019-10117-3C06 against A/Perth/16/2009 (H3N2) HA mutant virus libraries (Lee et al., 2018) using a previously described protocol (Doud et al., 2017) . We selected two biological replicate libraries by incubating 1e6 TCID 50 mutant viruses with neutralizing concentrations of antibody at 37°C for 1.5 hours. For antibody 024-10128-3C04, we neutralized mutant viruses with 0.1, 0.25, 0.2, 0.65, or 1 μg/ml antibody, and for 019-10117-3C06, we neutralized with 0.1, 0.2, 0.25, 0.55, 0.7, or 1 μg/ml antibody. We also included a mock selection condition where virus library was incubated with Influenza Growth Media (IGM, consisting of Opti-MEM supplemented with 0.01% heat-inactivated FBS, 0.3% BSA, 100 U of penicillin per milliliter, 100 μg of streptomycin per milliliter, and 100 μg of calcium chloride per milliliter). Following antibody incubation, we infected 2.5e5 MDCK-SIAT1-TMPRSS2 cells with the virus-antibody mixture, then 2 hours post-infection aspirated off the inoculum, washed the cells with 1 mL PBS, then replaced the media with fresh IGM. Approximately 15 hours post-infection, we extracted, reverse-transcribed, and PCR amplified the viral RNA. We used the barcodedsubamplicon sequencing approach described in Lee et al., 2018 to deep sequence at highaccuracy. We then used dms_tools2 (v2.3.0) (Bloom, 2015) to analyze the deep sequencing results.
ELISAs with Human Sera-ELISA plates were coated the day prior with 0.5 μg/mL recombinant HAs (A/Hong Kong/4801/2014 WT, A/Hong Kong/4801/2014 Y98F, or a PBS background control) and blocked for 2 hr on the day of the experiment with a 3% BSA in PBS solution. After washing the plates three times with wash buffer containing 0.5% Tween20 (vol/vol) in PBS (PBS-T), serially diluted serum samples were added to the ELISA plates and incubated for 2 hr. After incubation, plates were washed three times with PBS-T and a peroxidase-conjugated goat anti-human secondary antibody diluted in 1% BSA in PBS was added. After 1 hr of incubation with the secondary antibody, plates were washed three times with PBS-T and 50 μL of a TMB substrate was added to each well. 25 μL of 250mM HCl was used to quench the reaction and the absorbance at 450 nm was measured using a plate reader. Background signal at each dilution was subtracted for each serum sample and one site -specific binding curves were fit to the data using GraphPad Prism. Human sera ELISAs were performed in triplicate on separate days.
Competition ELISAs-ELISA plates were coated the day prior with BPL-inactivated A/ Hong Kong/1/1968 virus and blocked for 2 hr with a 3% BSA in PBS solution. After washing the plates five times with distilled water, serial dilutions of the anti-H3 mouse mAb F49 or the control mouse mAb C179 in 1% BSA in PBS were added to the plate and incubated for 2 hr at RT. After incubation, human mAbs were added directly to the plates at a fixed concentration in 1% BSA in PBS and incubated for 1 hr at RT. Plates were then washed five times with distilled water and peroxidase-conjugated anti-human secondary antibody was added and incubated for 1 hr. Following incubation with secondary antibodies, plates were washed five times with distilled water, TMB substrate was added, and the reaction was quenched with HCl. The absorbance at 450 nm was quantified using a plate reader and competition at each dilution was normalized to the control mAb C179.
Foci-Reduction Neutralization Tests (FRNTs)-mAbs or RDE-treated serum samples
were serially diluted in 96-well plates in a total volume of 50 μL. Approximately 200-300 focus-forming units of virus in 50 μL were added to each well and the virus-absorbed sera mixture was incubated for 1 hr at room temperature. After incubation, the virus-sera mixture was added to confluent monolayers of MDCK-SIAT1 cells and incubated for 1 hr at 37°C. After incubation, cell monolayers were washed with 180 μL serum-free MEM and an overlay medium containing HEPES, gentamycin, and 0.5% methylcellulose was added. The cell monolayers were incubated for 18 hr, after which the overlay was removed and the cells were fixed at 4°C for 2 hr using an aqueous solution of 4% paraformaldehyde (vol/vol). After fixation, cell monolayers were permeabilized using 0.5% Triton X-100 in PBS (vol/ vol). After fixation and permeabilization, monolayers were blocked with a solution of 5% fat-free milk in PBS for 1 hr. After blocking, a mouse anti-nucleoprotein antibody was added in 5% milk/PBS for 1 hr. After the primary incubation, a peroxidase-conjugated goat antimouse secondary antibody in 5% milk/PBS was added for 1 hr. After incubation with the secondary antibody, monolayers were stained using a TMB substrate and foci were imaged and quantified using an ELISpot reader. For staining, plates were washed with distilled water between each step. Percentage of infection was determined relative to wells that did not receive any serum or antibody. FRNT90 titer values are reported as the concentration of serum or mAb that reduced the numbers of foci by at least 90%.
Absorption-Neutralization and Absorption-ELISA Assays-Two days prior to experiments, 293F suspension cells were transfected using 293fectin with plasmids expressing A/Hong Kong/4801/2014 WT HA, A/Hong Kong/4801/2014 Y98F HA, or a mock transfection control containing no plasmid or transfection reagent. On the day of the experiment, transfected cells were pelleted by centrifugation, washed twice with 293F media, and resuspended at the desired volume. In the case of absorption-neutralization assays, RDE-treated serum samples were diluted in 293F media at a dilution of 1:10 and split into three fractions for the three absorption conditions. An equivalent volume of 293F media containing approximately 8×10 6 transfected cells/absorption reaction was added to each diluted serum sample and the samples were mixed by shaking for 1 hr at room temperature. After incubation, the cells were pelleted by centrifugation and the supernatant was transferred and re-centrifuged to clarify. Absorbed supernatant containing the sera was then serially diluted in 96-well round-bottom plates in serum-free MEM and FRNT assays were conducted as described. Absorption-neutralization experiments were completed in triplicate on separate days. In the case of absorption-ELISA assays, serum samples were diluted in 293F media at an initial dilution of 1:50 and split into three fractions for the three absorption conditions. Transfected cells were added and absorption of serum antibodies was carried out as described above. Following absorption, absorbed serum samples were serially diluted at a starting dilution of 1:500 (factoring in absorption volume) in 1% BSA w/vol in PBS and ELISAs were performed as described above.
For ELISA data, background antibody binding for each sample at each dilution was subtracted and one-site specific binding curves were fit to the data using GraphPad Prism software. The area under the curve (AUC) was calculated for each curve. For neutralization data, foci in positive control wells which did not receive any serum or antibody were used to determine percentage of infection. Neutralization data are represented as percentage of neutralization at each dilution of serum, and a four-parameter [inhibitor] versus doseresponse curve was fit to each set of neutralization data using GraphPad Prism, with top and bottom values constrained to 100 and 0, respectively. Assays were performed at least three times on separate days. For both absorption-neutralization and absorption-ELISA experiments, the RBS mAb 019-10117 3C06 mAb and the 041-10047 1C04 mAb (which targets the lower HA head region) were initially diluted to a concentration of 32 μg/mL in 293F media before adding to cells. For absorption-neutralization experiments, the starting concentration for each mAb absorption condition in the FRNT was 16 μg/mL. For absorption-ELISA experiments, the starting concentration for each mAb absorption condition in the ELISA was 3.2 μg/mL.
QUANTIFICATION AND STATISTICAL ANALYSIS
Titer values for neutralization and ELISA experiments are reported as geometric mean and geometric SD, geometric mean and geometric 95% CI, or mean ± SEM as noted in each figure legend. For statistical analysis, the statistical tests used and the significance thresholds are described in the legend of each figure. Statistical analyses of differences between mAb neutralization (FRNT) titers against the WT and each mutant virus were completed using a one-way ANOVA with Dunnett's test for multiple comparisons. To determine whether individuals had lower neutralization titers to the circulating strain A/Hong Kong/4801/2014 compared with the vaccine strain A/Switzerland/9715293/2013 we used the paired, nonparametric Friedman test with correction for multiple comparisons. For absorption-ELISA experiments, the area under the curve (AUC) was determined for each experimental condition and the triplicate AUC values for the WT absorption condition and the Y98F mutant absorption condition were compared using an unpaired Student's t test. All statistical analysis was performed in GraphPad Prism software. Each mAb was tested for binding to a panel of HAs with different substitutions. (A and B) The locations of HA substitutions in classic antigenic sites are shown on the H3 trimer (A) (PDB 4O5I), and the locations of RBS substitutions are shown on an H3 HAsialic acid co-crystal structure (B) (PDB 2YP8). Most substitutions did not affect glycosylation, with the exception of the K160T substitution that results in the addition of a glycan at N158 (shown in red) and the N285Y substitution that results in the loss of a glycan at 285 (shown in orange). (C) ELISAs were completed using plates coated with VLPs bearing WT HA and HAs with different substitutions. Numbers in squares indicate fraction of binding relative to VLPs with A/Victoria/210/2009 WT HA. Colors of each square range from white (0% of binding to WT) to black (100% of binding to WT). Binding values are the average of two independent experiments.
Figure 3. Binding of mAbs to Historical H3N2 Strains
ELISAs were completed with each mAb and a panel of historical H3N2 strains and the A/ California/07/2009 H1N1 strain. Colors of each square range from white (0% of binding to WT) to black (100% of binding to WT). Binding values are the average of three independent experiments, while the value in each square indicates the fraction of binding relative to the A/Victoria/210/2009 vaccine strain. H3N2 strain information is reported in the Key Resources Table. Zost et al.
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Author Manuscript (C-E) Neutralization assays were completed with viruses that had several of the substitutions identified in deep mutational scanning experiments. Each panel shows neutralization of a single mAb against WT virus and viral mutants identified by mutational antigenic profiling. A red dashed line indicates the limit of detection (each mAb was tested at a starting concentration of 16 μg/mL). Neutralization titers shown are the geometric mean, and error bars denote the geometric SD of three independent experiments. Statistical analyses of differences between neutralization (FRNT) titers against WT and mutant viruses were done using a one-way ANOVA with Dunnett's test for multiple comparisons. *p < 0.05. 
